

Small Cell Lung Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/S5A2A72B5FDEN.html>

Date: March 2021

Pages: 240

Price: US\$ 3,000.00 (Single User License)

ID: S5A2A72B5FDEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Small Cell Lung Cancer – Pipeline Insight, 2021," report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Small Cell Lung Cancer Understanding

Small Cell Lung Cancer: Overview

Small cell lung cancer accounts only for 13% of the lung cancers. However, SCLC is the more aggressive form of lung cancer. With SCLC, the cancer cells tend to grow quickly and travel to other parts of the body, or metastasize, more easily. Small cell lung cancer is more strongly linked to smoking. Small cell lung cancer typically have had relatively very few symptoms. The symptoms can result from local growth of the tumor, spread to nearby areas, distant spread, paraneoplastic syndromes, or a combination thereof. SCLC diagnosis begins with a thorough physical examination and medical history. When SCLC reaches the extensive stage, treatment is aimed at relieving symptoms, not at curing the disease.

'Small Cell Lung Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.

Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Small Cell Lung Cancer Emerging Drugs

HLX-10: Henlix Biotech

HLX10 in combination with chemotherapy can be potentially used for the treatment of metastatic esophageal squamous-cell carcinomas (mESCC), squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), gastric cancer (GC) and cervical cancer (CC). Currently the patient enrollment has started in phase III for the treatment of extensive small cell lung cancer.

Tiragolumab: Genentech

Tiragolumab (anti-TIGIT, MTIG7192A, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). Clinical trials for Tiragolumab are being conducted by Genentech for the treatment of patients with small cell lung cancer.

Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc γ R on macrophages. Tislelizumab was designed to bind to PD γ 1, a cell surface receptor that plays an important role in allowing tumor cells to evade the immune system. Tislelizumab is in phase III clinical trials for small cell lung cancer.

Lucitanib: Haihe Bipharma

Lucatinib is an oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR γ /? γ , with significant efficacy and high safety. Rapid oral absorption being studied in phase II/III for the treatment of small cell lung cancer.

LP002: Taizhou HoudeAoke Biomedical Co., Ltd.

LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. LP002 clinical trials are being conducted in phase II for the treatment of Small cell lung cancer.

LY 01610: Luye Pharma Group, Ltd

LY01610 is a DNA topoisomerase inhibitor being developed by Luye Pharma for the treatment of patients with small cell lung cancer.

Further product details are provided in the report.....

Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Small Cell Lung Cancer

There are approx. 200+ key companies which are developing the therapies for Small Cell Lung Cancer. The companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Henlix Biotech

Phases

DelveInsight's report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Cell Lung Cancer drugs.

Small Cell Lung Cancer Report Insights

Small Cell Lung Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Small Cell Lung Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Small Cell Lung Cancer drugs?

How many Small Cell Lung Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Small Cell Lung Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Small Cell Lung Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Small Cell Lung Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Small Cell Lung Cancer companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Small Cell Lung Cancer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

HLX-10: Henlix Biotech

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

LP002: Taizhou HoudeAoke Biomedical Co., Ltd.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

APG-1252: Ascentage Pharma Group Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Small Cell Lung Cancer Key Companies

Small Cell Lung Cancer Key Products

Small Cell Lung Cancer- Unmet Needs

Small Cell Lung Cancer- Market Drivers and Barriers

Small Cell Lung Cancer- Future Perspectives and Conclusion

Small Cell Lung Cancer Analyst Views

Small Cell Lung Cancer Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Small Cell Lung Cancer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Small Cell Lung Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Small Cell Lung Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/S5A2A72B5FDEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S5A2A72B5FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970